SM
HRTX icon

SG3 Management’s Heron Therapeutics HRTX Stock Holding History

SG3 Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,000
Closed -$535K – 1157
2021
Q1 		$535K Buy
33,000
+29,000
+725% +$517K 0.01% 761
2020
Q4 		$85K Buy
+4,000
New +$69.5K ﹤0.01% 939

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

SG3 Management's HRTX Position: Q1 2022 in Review

SG3 Management sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 27,904 shares — an estimated $255K sold.

SG3 Management first reported a position in HRTX in Q4 2021 and held it in 1 quarter. The position peaked at $255K in Q4 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • SG3 Management reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 27,904 Heron Therapeutics shares in Q1 2022, an estimated $255K.
  • SG3 Management first reported a position in Heron Therapeutics in Q4 2021 and held it in 1 quarter.
  • SG3 Management's Heron Therapeutics position peaked at $255K in Q4 2021.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.